Hyderabad-based Bharat Biotech on Wednesday (12 January) said that the booster dose of its COVAXIN Covid-19 vaccine neutralises both Omicron and Delta variants of the Coronavirus.
"Booster dose of COVAXIN generated robust neutralizing antibody responses against both Omicron and Delta," the company said in a statement.
Bharat Biotech added that 100 per cent of test serum samples showed neutralisation of the Delta variant and more than 90 per cent of test serum samples showed neutralisation of the Omicron variant.
"These data add to the body of evidence that the broad-spectrum mechanism of action of a whole virus inactivated Covid-19 vaccine, like COVAXIN, is a viable option in this continously evolving pandemic" the Company said.
The COVAXIN, which was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), was approved by the World Health Organisation for emergency use in November.
The Covaxin and Serum Institute of India's Covishield together are the most widely used vaccines in the mega COVID-19 vaccination drive in the country.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.